This review focuses on progress made in the field of gastric motility in the past year, emphasizing advances in understanding the motor physiology of the stomach in health and disease; noninvasive imaging technology and data on novel pharmacotherapeutics and other therapeutic interventions for gastroparesis.
Introduction
Functional dyspepsia is defined as persistent or recurrent pain or discomfort in the upper abdomen that is not relieved by defecation or caused by organic disease. Organic disease is generally excluded by a normal endoscopy or imaging studies. Improved understanding of the molecular mechanisms regulating smooth muscle function, novel diagnostic modalities, and new specific therapeutics may redefine some of the functional dyspepsia as genuine pathophysiological gastric motility disorders.
Gastric motility: pattern in health
The main motor function of the stomach is to serve as an active reservoir that stores and mixes ingested food as well as modulates its rate of subsequent transfer into the duodenum. Noncontractile gastric slow waves, at a frequency of three cycles per minute, originate at a site referred to as the gastric pacemaker along the greater curvature in the proximal to middle corpus and migrate in both circumferential and longitudinal directions. Superimposed spike waves, when the slow wave reaches a mechanical threshold, are responsible for actual contractions [1] . The interstitial cells of Cajal (ICCs), situated within the myenteric plexus, are thought to be the pacemakers and regulators of gut motor function [2] .
Recent observations of electrical propagation in guinea pig gastric antrum suggest that the slow oro-anal progression of slow waves at speeds of 2.5 mm/s results from a slow conduction velocity of pacemaker potentials in the myenteric network of the ICCs whereas the rapid circumferential conduction of slow waves at speeds of 13.9 mm/s results from the electrical properties of intramuscular ICCs [3 ] . Thus, a complex interplay generates the full spatio-temporal pattern of gastric peristalsis.
In a further study, utilizing guinea pig gastric smooth muscle, it was shown that the activity of protein kinase C modulates the frequency and the intracellular calcium concentration modulates the amplitude of slow waves [4 ] . Calcium was released from internal stores in response to increased metabolic activity of the mitochondria. Thus, decreased activity of mitochondria, especially in chronic illness, may play a key role in determining the frequency of spontaneous activity in gastric pacemaker cells.
Gastric and duodenal motility influence each other via release of neurotransmitters and hormones. For example, distension of the antrum causes relaxation of the pylorus (antro-sphincteric reflex) and duodenum (antro-duodenal reflex), distension of the duodenum causes antral relaxation (duodeno-antral reflex), and distension of the pyloric sphincter causes antral contraction (sphinctero-antral reflex) [5 ,6 ] . These reflexes facilitate the transport of gastric contents into the duodenum.
Gastric motor activity in disease
Gastroparesis is characterized by delayed gastric emptying in the absence of mechanical obstruction. Abnormal gastrointestinal motility is seen in a third of diabetic patients as well as in patients with chronic neurological and rheumatological conditions, renal failure, and cirrhosis [7] . The precise pathogenesis is not known but disturbances in the functioning of vagal neurons, enteric neurons, ICCs, smooth muscle cells, or humoral factors are suspected [8] . Genetic factors also contribute since gastric dysmotility occurs predominantly in females. Recently, it was shown that healthy female rats exhibit increased gastric neural nitric oxide synthase (nNOS) expression whereas diabetic female, but not male, rats exhibit significantly decreased nNOS expression as well as impaired nitrenergic relaxation [9 ] . ICCs express KIT protein or CD117, a transmembrane receptor with tyrosine kinase activity. Immunostaining of full thickness antral biopsies obtained from 14 medically refractory gastroparetic patients undergoing placement of a gastric electrical stimulator showed absence of ICCs in one-third of the patients [10]. Interestingly, these patients had more severe abnormalities in generating slow waves and responded less well to the electrical stimulator.
Diagnostic modalities
The gold standard for assessing gastric emptying is scintigraphy. Measurement of the emptying of solids is more sensitive for detection of gastroparesis than liquids. Solid emptying exhibits a lag phase followed by a prolonged linear emptying phase. Unexpectedly, the prime abnormality in patients with dyspepsia and autonomic dysfunction appears to be rapid gastric emptying [11 ] . Accelerated early phase emptying may lead to delayed late phase emptying due to feedback inhibition by the duodeno-antral reflex [5 ,12 ] . Treatment with prokinetics may actually worsen dyspepsia in these patients. Thus, imaging should begin soon after ingestion of the meal and continue for up to 4 h postprandially. Regional analysis should be included as abnormal distribution of the meal in the stomach may explain dyspeptic symptoms when global emptying values are normal [13 ].
The term 'gastric accommodation' was introduced almost 100 years ago [14] . As understood today, it involves both receptive relaxation upon bolus deglutition and adaptive relaxation in response to increases in intragastric pressure induced by food in the stomach. Impaired accommodation appears primarily responsible for the fullness sensation in dyspepsia [15] .
The intragastric barostat, although generally considered the gold standard for assessing accommodation, is unphysiologic and has poor reproducibility [16] . The satiation drinking test, although less invasive, similarly has poor reproducibility. A novel scintigraphic method for simultaneously assessing gastric accommodation and emptying has been developed at Temple University using dualisotopes, either (99 m)Tc-pertechnetate intravenously and (111)In-diethylenetriaminepentaacertic acid in a liquid nutrient drink or an (111)In-oxine-labeled egg sandwich meal. Emptying and accommodation were measured using single positron emission computer tomography (SPECT) every 20 min up to 240 min. Gastric accommodation was calculated as the percentage change in planar (two-dimensional) gastric cross-sectional area using a left anterior oblique planar projection and the percentage change in total SPECT 3-dimensional gastric counts compared with the baseline image [17] . Further data and validation of the methodology, which offers a comprehensive assessment of gastric motor function, are eagerly awaited.
High-resolution functional ultrasound with Doppler imaging enables timing of postprandial dyspeptic symptoms and transpyloric passage of gastric contents with great temporal and spatial resolution, and may be used to assess the effects of pharmacological intervention. It also can be used to evaluate antral contractility, gastric emptying, transpyloric flow, intragastric distribution of meals, and gastric accommodation The Ultrasound Meal Accommodation Test (U-MAT), a three-dimensional ultrasound and Doppler imaging test, has recently been described and used to characterize patients with organic and nonorganic dyspepsia [18 ] . This technique permits measurement of most parameters of gastric motility in a dynamic and physiological state but may not be suitable for obese subjects.
MRI, using three-dimensional volume scans and twodimensional dynamic scans, reliably assesses gastric emptying and may be superior to intragastric barostat to assess gastric accommodation [19, 20 ] . The psychological impact of being inside a scanner and cost may prevent extensive applicability of this technique.
Pharmacological options in gastroparesis
Pharmacological options for gastroparesis are still limited to a few available prokinetics, each with its own limitations. Metoclopramide may induce anxiety, tremors, dystonia, Parkinson's like symptoms, and depression. Erythromycin has a narrow therapeutic window and high incidence of tachyphylaxis, disrupts the bacterial flora, promotes antimicrobial resistance, and may induce cardiac arrythmias [21] .
Cisapride has been severely restricted due to risk for prolongation of the cardiac QT interval. Domperidone, a dopamine antagonist with particular affinity for the D2 subtype receptors in the brain and the peripheral nervous system, improves gastrointestinal transit. Unlike metoclopramide, domperidone minimally crosses the bloodbrain barrier and has few, if any, central nervous system side effects. Although hyperprolactinemia may occur, galactorrhea is rare. Domperidone is available in 58 countries, but only through a compassionate clearance program in the United States for patients with medically refractory gastroparesis. An annually renewable investigational new drug application and informed consent documents are required. Pretreatment and annual ECG and serum potassium are recommended; additional information can be obtained at the website http://www.fda. gov/cder/news/domperidone.htm [22 ] .
Tegaserod has recently been withdrawn from the United States market due to cardiovascular side effects. A recent double blind placebo controlled randomized trial found that tegaserod had no significant effects on gastric motor, sensory, or myoelectric function in healthy volunteers using the SPECT technique [23 ].
The earlier developed motilin receptor agonist, ABT-229, failed to show significant efficacy in relieving symptoms in patients with gastroparesis or functional dyspepsia [24] . A newer motilin agonist, mitemcinal, produced a significantly better response rate than placebo in symptomatic diabetic patients with body mass index <35 kg/m 2 and hemoglobin A1 c <10%. Subanalysis suggested that the improvement was more impressive in patients with nondelayed gastric emptying [25 ] .
Itopride, a dopamine (D 2) antagonist with antiacetylcholinesterase effects, showed superiority over placebo and effects similar to that of domperidone in patients with functional dyspepsia [26, 27, 28 ] . In healthy subjects evaluated by SPECT, itopride reduced total postprandial gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function [29 ] . In US studies, however, itopride did not demonstrate a statistically significant effect on the symptoms of upper abdominal pain and fullness or the Patient Global Assessment questionnaire in patients with functional dyspepsia.
Ghrelin, a peptide present in gastric oxyntic mucosa and neurons, enhances gastric emptying and accelerates fasting motility [30, 31 ] . In idiopathic gastroparesis, administration of ghrelin enhanced gastric emptying and improved meal-related symptoms suggesting a potential for ghrelin receptor agonists in the treatment of gastroparesis [32 ] .
A meta-analysis of 27 studies evaluating the effects of prokinetic agents in patients with functional dyspepsia, including a total of 1844 subjects that were assigned to an experimental arm, and 1591 subjects assigned to a placebo arm, was published. Cisapride was the most commonly used interventional drug (22 trials), followed by domperidone (six trials), mosapride (three trials), metoclopramide (one trial), and trimebutine (one trial). The interventional drugs had 30% excess probability to produce a treatment response compared with placebo. The interventional periods, however, were short (range 2-6 weeks) and the year of publication showed the most statistically significant effect with the difference gradually decreasing with advancing year of publication [33 ]. Further studies are required to understand the mechanism of action of individual agents in terms of accommodation and gastroparesis as well as long-term efficacy.
Botulinum toxin and manipulation of gastric emptying
Botulinum toxin (BTx) A inhibits acetylcholine release from cholinergic nerves [34] . BTx enters neurons by binding to the synaptic vesicle protein SV2 then cleaves the soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) protein synaptosomal associated protein (SNAP)-25 leading to inability of synaptic vesicles containing acetylcholine to undergo exocytosis. Increased gastric outlet resistance due to pylorospasm has been described, particularly in diabetic gastroparesis. Intrapyloric injection of BTx (4 Â 25 units) enhanced solid, but not liquid, emptying in 20 patients [35 ] . Postprandial fullness, bloating, nausea, and belching also improved. In a 3-year follow-up study, intrapyloric BTx injection eliminated postoperative gastroparesis in 11 of 12 patients after esophagectomy [36 ] .
BTx injection into the stomach has been used in an attempt to facilitate weight loss by reducing gastric accommodation. Compared to placebo, BTx injection (200 units) into the fundus and antrum of the stomach of 24 morbidly obese patients reduced maximal gastric capacity and induced weight loss [37 ]. These results, however, could not be reproduced in two other studies [38 ,39 ] .
Neural stem cell transplantation
Nitric oxide is a major inhibitory neurotransmitter in the enteric nervous system that causes smooth muscle relaxation. Neural stem cells implanted into the stomachs of nNOS deficient mice, differentiated, within 1 week, into nNOS expressing neurons. This was accompanied by improvement in gastric emptying [40] .
Gastric electrical stimulation
Various modalities of gastric electrical stimulation have been tried to improve nausea, vomiting, nutritional status, quality of life, and gastric emptying. Stimulation at or just above the intrinsic slow wave frequency, termed gastric pacing or low-frequency stimulation, appeared to improve symptoms and emptying of solids in nine patients with medically refractory gastroparesis when administered via a portable stimulator over 3 months [41] .
More recently, a broad range of supraphysiological high frequency gastric stimulation has been described. In a randomized double-blind crossover designed study, 33 drug refractory gastroparetic patients (17 diabetic and 16 idiopathic) received continuous high-frequency/ low-energy gastric electrical stimulation via electrodes in the muscle wall of the antrum [42] . In the double-blind portion of the study, self-reported vomiting frequency was significantly reduced in those stimulated and this was consistent with the significant patient preference to have the stimulation on. In the unblinded portion of the study, vomiting frequency decreased significantly, paralleling improvement in symptom severity and quality of life at both 6 and 12 months. Interestingly gastric emptying was only modestly accelerated. Five patients had their gastric electrical stimulation system explanted or revised because of infection or other complications. In a followup beyond 3 years in 37 patients, total symptom score, hospitalization days, and the use of medications were all significantly reduced at 1 year and were sustained beyond 3 years. The mean HbA1c level in diabetic patients was significantly reduced from 9.5 to 7.9% at 3 years [43 ] .
In a three-center long-term follow-up (median 4 years), from January 1992 through January 2005, most patients implanted (135 of 156) were alive with intact devices, significantly reduced gastrointestinal symptoms, and improved health-related quality of life, with evidence of improved gastric emptying [44 ] . Most patients explanted, usually for pocket infections, were later reimplanted successfully. There were no deaths directly related to the device. Although these studies appear to have impressive therapeutic response that cannot be discounted for as a placebo response, the precise mechanisms for the responses are unclear.
Technique for the placement of temporary gastric electrical stimulation electrodes endoscopically or via a gastrostomy site has been described [45] . This would allow rapid assessment to select appropriate candidates for the permanent surgical placement of the device.
Animal studies reveal that four-channel gastric electrical stimulation was able to completely entrain the slow waves in the entire stomach using only 1% of the energy required by one-channel gastric electrical stimulation and may be better at increasing gastric emptying [46] . Incremental risks associated with duration and complexity of the procedure include perforation, infection, and lead malfunction.
Induction of reverse gastric electrical stimulation by direct stimulation of the pylorus has been investigated only preliminarily as a means to delay emptying, induce satiety, and achieve weight loss in animals and humans [47 -51 ] .
Conclusion
The pathophysiology and treatment of dyspepsia remains an enigma. Progress is being made, however, in the diagnosis and treatment of gastroparesis. The development of wireless technology to sequentially activate embedded gastric electrical stimulators may be the next step in the evolution of the new and exciting field of therapeutic gastric electrophysiology. Potentially this technology could be extended throughout the gut to, in addition, treat colonic inertia and other disorders of gut motility.
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